Gynecologic Oncology Update

Featuring an interview with Dr Ramez Eskander, including the following topics:
Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00)
Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53)
Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58)
Current and investigational targets of ADCs in gynecologic cancers (17:14)
Current research surrounding raludotatug deruxtecan (R-DXd) and its potential role in clinical practice (21:56)
Safety and tolerability profiles of ADCs, including R-DXd, and potential mitigation strategies (27:36)
Overview of available TROP2-directed ADCs for gynecologic cancers, including key clinical data (33:34)
Evolving use of TROP2-directed ADCs for gynecologic cancers in clinical trials (39:05)
Oral mucositis/stomatitis associated with TROP2-directed ADCs and potential mitigation strategies (44:38)

CME information and select publications

Featuring perspectives from Dr Bradley J Monk, Dr David M O’Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O’Malley, including the following topics:
Introduction (00:00)
Overview of Ovarian Cancer (OC) (2:12)
Role of PARP Inhibitors in Advanced OC (4:56)
Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45)
Role of Relacorilant in Advanced OC (57:08)
Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12)

NCPD information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Brian M Slomovitz and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:
Introduction (00:00)
Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer (EC) — Dr Backes (1:50)
Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced EC — Dr Westin (33:15)
Promising Agents Under Investigation for EC — Dr Slomovitz (1:01:41)

CME information and select publications

Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics:
Introduction (00:00)
Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander (2:40)
Strategies Targeting Folate Receptor Alpha in Advanced OC — Dr Matulonis (27:41)
Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC — Dr Moore (52:12)
Other Novel Agents and Strategies for Advanced OC — Dr O'Malley (1:14:35)
Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC — Dr Olawaiye (1:39:39)

CME information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:
Case: A woman in her late 60s presents with mismatch repair-deficient metastatic endometrial cancer(00:00)
Perspectives on neoadjuvant immunotherapy for microsatellite instability-high endometrial cancer (06:25)

CME information and select publications